Jeffrey Stuart Peters - Feb 5, 2024 Form 4 Insider Report for MACROGENICS INC (MGNX)

Signature
/s/ Lynn M. Cilinski, Attorney-in-fact
Stock symbol
MGNX
Transactions as of
Feb 5, 2024
Transactions value $
-$410,786
Form type
4
Date filed
2/7/2024, 04:17 PM
Previous filing
Mar 14, 2023
Next filing
Feb 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $625K +54.4K $11.50 54.4K Feb 5, 2024 Direct
transaction MGNX Common Stock Options Exercise $222K +21.9K +40.23% $10.15 76.3K Feb 5, 2024 Direct
transaction MGNX Common Stock Sale -$897K -54.4K -71.31% $16.50 21.9K Feb 5, 2024 Direct F1
transaction MGNX Common Stock Sale -$361K -21.9K -100% $16.50 0 Feb 5, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee stock option (right to buy) Options Exercise $0 -54.4K -83.33% $0.00 10.9K Feb 5, 2024 Common Stock 54.4K $11.50 Direct F2
transaction MGNX Employee stock option (right to buy) Options Exercise $0 -21.9K -31.25% $0.00 48.1K Feb 5, 2024 Common Stock 21.9K $10.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022.
F2 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.